NCT02514239View on ClinicalTrials.gov

Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

July 8, 2015

Primary Completion Date

July 17, 2018

Study Completion Date

July 2, 2020

Conditions
Multiple Myeloma
Interventions
DRUG

BI 836909

Intravenous Infusion of BI 836909.

Trial Locations (5)

31059

INS Universitaire du Cancer, Toulouse

44000

HOP Hôtel-Dieu, Nantes

59037

HOP Claude Huriez, Lille

89081

Universitätsklinikum Ulm, Ulm

97080

Universitätsklinikum Würzburg, Würzburg

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY